Tirzepatide

Description

Tirzepatide is an investigational, weekly, subcutaneous peptide that functions as a dual agonist, targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Developed for the study of obesity and type 2 diabetes management, it has demonstrated significant efficacy in clinical trials, showing potential for substantial weight reduction and metabolic improvement.

Key Details

• Mechanism: Dual-action targeting of both GIP and GLP-1 receptors to enhance satiety, improve insulin sensitivity, and regulate glucose metabolism more effectively than single-receptor agonists.

• Status: Extensively evaluated in major clinical trials (such as the SURMOUNT program), showing profound impacts on body weight composition and glycemic control.

• Application: Utilized in laboratory research settings to evaluate synergistic incretin receptor pathways, metabolic expenditure, and advanced weight loss mechanisms.